Glomerulonephritis is an indication for drug development with over 110 pipeline drugs currently active. According to GlobalData, preregistered drugs for Glomerulonephritis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Glomerulonephritis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Glomerulonephritis overview
Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat (strep throat), immune diseases such as lupus, type 1 and type 2 diabetes, and viral infections such as HIV, hepatitis B virus, and hepatitis C virus. Risk factors include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis, and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, and welling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis and can include medications, lifestyle changes, dialysis, and transplant.
For a complete picture of PTSR and LoA scores for drugs in Glomerulonephritis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
